<DOC>
	<DOCNO>NCT01077713</DOCNO>
	<brief_summary>This 2 arm study evaluate efficacy safety Avastin + gemcitabine , Avastin + gemcitabine + attenuate dos cisplatin , first line treatment elderly patient non-squamous non-small cell lung cancer . Patients randomise receive either Avastin 7.5mg/kg iv day 1 + gemcitabine 1200mg/m2 day 1-8 3 week cycle , Avastin 7.5mg/kg iv day 1 + cisplatin 60mg/m2 day 1 + gemcitabine 1000mg/m2 day 1-8 3 week cycle . After 6 cycle combination therapy , patient continue receive Avastin monotherapy . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Gemcitabine With Without Cisplatin First-Line Treatment Elderly Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient , &gt; =70 year age ; inoperable , locally advanced , metastatic nonsquamous nonsmall cell lung cancer ; &gt; =1 measurable lesion ; ECOG performance status 01. neoadjuvant/adjuvant chemotherapy within 6 month prior enrollment ; radical radiotherapy curative intent within 28 day prior enrollment ; history &gt; =grade 2 hemoptysis 3 month prior enrollment ; evidence CNS metastases ; current recent ( within 10 day first dose Avastin ) use aspirin ( &gt; 325 mg/day ) full dose anticoagulant thrombolytic agent therapeutic purpose .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>